Levitra Effective in Men with ED, Cardiovascular Problems

Susan Farley
Published Online: Thursday, February 1, 2007

A recent trial determined that using vardenafil HCl (Levitra) to treat erectile dysfunction (ED) in men with cardiovascular-related conditions showed the first dose to be more effective than placebo. The cardiovascular conditions reviewed included high blood pressure, high cholesterol, and/or diabetes. The randomized, placebo-controlled study of 600 patients with ED used a single, openlabel, 10-mg dose of vardenafil. After completing the sexual encounter profile (SEP), success was determined by penetration (SEP-2) and erection maintenance until completion of intercourse (SEP-3). In the 1-week period, 87% of patients using vardenafil were successful with SEP-2, and 74% were successful with SEP-3. SEP-2 success was achieved in 84% of men with high blood pressure, 84% of men with high cholesterol, and 75% of men with diabetes. Participants who achieved SEP-2 success were randomized to receive vardenafil or placebo for an additional 12 weeks. At the end of that portion of the study, those taking the 10-mg vardenafil had an SEP-2 success rate of 83%, compared with 56% for those taking placebo. Results were published in the November 2006 issue of the International Journal of Clinical Practice.

Ms. Farley is a freelance medical writer based in Wakefield, RI.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues